Worm products and methods of use
AssigneeAarhus Universitet
InventorsPeter Nejsum, Martin Roelsgaard Jakobsen, Sidsel Dahl Andersen, Christian Krapp
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a composition comprising a helminth product for prevention, treatment and/or amelioration of a clinical condition associated with the RIG-LISTING and TLR pathways. Specifically, the composition is provided for use in the treatment of clinical conditions associated with constitutive activation of type I interferon (IFN), including monogenic type I interferonopathies and inflammatory or autoimmune disorders. The present invention also relates to different methods of manufacturing a helminth product.
Claims21
1-57. (canceled)
A method of preventing, treating and/or ameliorating a clinical condition associated with the RIG-I/STING pathway, the method comprising administering a helminth product to an individual in need thereof, wherein the helminth product comprises a lysate or secretion of an Ascaridida worm and/or egg.
A method of manufacturing a helminth product comprising an extracellular vesicle-depleted fraction, the method comprising:
- a. providing Ascaridida worms and/or eggs,
- b. lysing the Ascaridida worms and/or eggs of a), thus providing a lysate such as worm body fluid, and
- c. fractionating the lysate of b) to generate an extracellular vesicle-depleted fraction.
Dependencies are inferred from the claim text.